January 5, 2018 / 12:34 PM / 15 days ago

BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc:

* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

* ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED

* ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY “INTREPID” OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED

* ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below